News
Kamada gets Israeli patent for Alpha-1 drug
Globes, Israel
ISRAEL — Drug developer Kamada Ltd. has received Israeli patent approval for the unique manufacturing process it has developed for cleaning and purifying AAT (Alpha-1 Antitrypsin). Kamada has received similar patent approvals in the U.S., Europe and Australia.
The patent protects Kamada’s unique protein proprietary technologies used to produce the company’s intravenous AAT drug, which is currently being marketed in six countries around the world, including the U.S. and Israel. It also protects the manufacturing process of the next generation product, inhalable AAT, which is currently undergoing Phase II/III clinical trials. In addition, Kamada’s technology is being used in an advanced clinical trial to treat juvenile Type-1 Diabetes.
The drug, which is being sold in the US under the commercial name, Glassia, treats chronic emphysema due to Alpha-1 Antitrypsin Deficiency, an under-diagnosed hereditary condition which can cause irreversible damage to lung tissue, severe lung disease, and even death.
